Ultrasound treatment of cutaneous side-effects of infused apomorphine: A randomized controlled pilot study

Movement Disorders

Volumn 24, Issue 1, 2009, Pages 115-118

  Poltawski, Leon ^a   Edwards, Hazel ^a   Todd, Amy ^a   Watson, Tim ^a   Lees, Andrew ^b   James, Cherry Ann ^c  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apomorphine; Clinical trial; Nodules; Parkinson's disease; Side effects; Therapeutic ultrasound

Indexed keywords

APOMORPHINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; FEMALE; HOME CARE; HUMAN; MALE; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN NODULE; SKINFOLD THICKNESS; ULTRASOUND THERAPY;

AGED; ANTIPARKINSON AGENTS; APOMORPHINE; DOPAMINE AGONISTS; DRUG ERUPTIONS; FEMALE; HARDNESS; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; SAMPLE SIZE; SUBCUTANEOUS TISSUE; ULTRASONIC THERAPY;

EID: 61449143704     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22316     Document Type: Article

References (20)

1. Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 2004;62(6 Suppl 4):S32-S36.
2. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine - an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004;21:687-709.
3. Hagell P, Odin P. Apomorphine in the treatment of Parkinson's disease. J Neurosci Nurs 2001;33:21-38.
4. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998;65:709-716.
5. Stocchi F, Farina C, Nordera G, Ruggieri S. Implantable venous access system for apomorphine infusion in complicated Parkinson's disease. Mov Disord 2001;14:358.
6. Nicolle E, Pollak P, Serre-Debeauvais F, et al. Pharmacokinetics of apomorphine in Parkisonian patients. Fundam Clin Pharmacol 1993;7:245-252.
7. Manson AJ, Hanagasi H, Turner K, et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001;124(Part 2):331-340.
8. Colzi A, Turner K, Lees A. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
9. Lees A, Turner K. Apomorphine for Parkinson's disease. Pract Neurol 2002:280-286.
10. Watson T. The role of electrotherapy in contemporary physiotherapy practice. Man Ther 2000;5:132-141.
11. Fischer A. Tissue compliance meter for objective, quantitative documentation of soft tissue consistency and pathology. Arch Phys Med Rehabil 1987;68:122-125.
12. Roberts KL. Reliability and validity of an instrument to measure tissue hardness in breasts. Australian J Adv Nurs 1998;16:19-23.
13. Fischer A. Algometry in diagnosis of musculoskeletal pain and evaluation of treatment outcome: an update. J Musculoskeletal Pain 1998;6:5-32.
14. Nussbaum E, Downes L. Reliability of clinical pressure-pain algometric measurements obtained on consecutive days. Phys Ther 1998;78:160-169.
15. Beggs I. Ultrasound of soft tissue masses. Imaging 2002;14:202-208.
16. Nessi R, Betti R, Bencini PL, Crosti C, Blanc M, Uslenghi C. Ultrasonography of nodular and infiltrative lesions of the skin and subcutaneous tissues. J Clin Ultrasound 1990;18:103-109.
17. Edwards H, Poltawski L, Todd A. Sonographic characterisation of tissue changes associated with infused apomorphine hydrochloride: a case series. Ultrasound 2008;16:155-159.
18. Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ 1995;311:1145-1148.
19. Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-1136.
20. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-157.